105P prognostic value of the NTRK fusion biomarker in the Netherlands

personalised medicineAnnals of Oncology

Sep 1

Written By Matthijs Versteegh

personalized medicine

Matthijs Versteegh

The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis